Nurix Therapeutics, Inc. 8-K

What Happened
Nurix Therapeutics announced a License and Collaboration Agreement with F. Hoffmann‑La Roche Ltd. and Genentech, Inc. (Roche) to develop, manufacture and commercialize bexobrutideg (NX‑5948), an oral, brain‑penetrant BTK degrader. The agreement was entered on June 6, 2026 (dated June 8, 2026) and Nurix disclosed the deal in an 8‑K filed June 8, 2026. Roche will pay $700.0 million upfront, and the parties may receive up to $2.3 billion in total payments (including the upfront) tied to development, regulatory and sales milestones.

Key Details

• Upfront payment: $700.0 million to Nurix; total potential deal value up to $2.3 billion (including upfront).
• Development and commercialization split: Global development costs shared 40% Nurix / 60% Roche (subject to exceptions).
• Territory responsibilities: Co‑develop and co‑commercialize in the United States (profits/losses shared equally); Roche has responsibility for development and commercialization outside the U.S. (Nurix eligible for tiered royalties on ex‑U.S. sales in the low‑ to high‑teens).
• Closing condition: Agreement becomes effective after applicable Hart‑Scott‑Rodino (HSR) and other antitrust waiting periods/clearances expire or are resolved.
• Term/rights: Product‑by‑product expiration terms; upon expiry Roche’s license for the applicable product/country becomes exclusive, fully paid‑up, irrevocable, perpetual and royalty‑free.

Why It Matters
This is a material business development for Nurix: the upfront cash improves liquidity immediately, while the cost‑share and co‑commercialization structure keeps Nurix involved in U.S. commercialization and lets Roche handle most ex‑U.S. commercialization. Investors should note the agreement is subject to antitrust clearances (HSR) and that Nurix will still fund 40% of global development costs and build/maintain a U.S. commercialization capability. The deal shifts commercial risk and upside between the parties (equal U.S. profit/loss sharing; ex‑U.S. royalties), and milestone/royalty payments could materially affect future revenue if bexobrutideg advances and is commercialized.